

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen [ID6462]

Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Alk-Abelló (Itulazax)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Anaphylaxis UK	Wales
Asthma Relief Charity	British National Formulary
Asthma + Lung UK	Care Quality Commission
Fifth Sense	Department of Health - Northern Ireland
NARA – The Breathing Charity	Healthcare Improvement Scotland
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
The Samter's Society	National Association of Primary Care
, and the second	National Pharmacy Association
Healthcare professional groups	NHS Confederation
Association for Respiratory	Scottish Medicines Consortium
Technology and Physiology	Welsh Government
 Association of Respiratory Nurse 	Welsh Health Specialised Services
Specialists	Committee
British Geriatrics Society	
British Paediatric Respiratory Society	Comparator companies
British Society for Allergy & Clinical	Allergy Therapeutics UK (Pollinex
Immunology	Grass)
British Society for Immunology –	
Clinical Immunology Professional	Relevant research groups
Network	Asthma, Allergy and Inflammation
British Thoracic Society	Research Trust
• ENT UK	British Association for Lung Research Cochrona Airwaya Crown
National Heart and Lung Institute	Cochrane Airways Group David Hide Asthma and Allergy
Primary Care Respiratory Society UK	David Hide Asthma and Allergy Page 17th Control Page 17th Contr
Royal College of General Practitioners	Research Centre
Royal College of Nursing	Genomics EnglandMRC Clinical Trials Unit
Royal College of Pathologists	MRC Clinical Trials Unit National Institute for Health Research
Royal College of Physicians	• Ivational institute for Health Research
Royal Pharmaceutical Society	Associated Public Health groups
Royal Society of Medicine	Associated Public Health groups

Final stakeholder list for the evaluation of betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen [ID6462] Issue date: November 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England 	Public Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Final stakeholder list for the evaluation of betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen [ID6462] Issue date: November 2024